OpenLB
Open Library of Bioscience
Advanced Search

Journal

Publication Year

1 year 3 years 5 years 10 years
2021 - 2032
202120222023
202420252026
202720282029
203020312032
2021 - 2032
202120222023
202420252026
202720282029
203020312032

Publication Type

Associated Data

Found 216 results

Filters: HPK1

Protein phosphatase 4 is a positive regulator of hematopoietic progenitor kinase 1.
Guisheng Zhou, Jonathan S Boomer, Tse-Hua Tan
J Biol Chem. Nov 19, 2004.279(47):49551-61 Print-Electronic
Source:PubMed
PMID: 15364934 doi:10.1074/jbc.M410317200
HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders.
Qin Wang, Xinyi Zhu, Jing Li, Sanjia Xu, Ali Wang, Xinwen Zhang, Xingxing Wang, Xiaopeng Cai, Haimei Xing, Ye Liu, Xuesong Liu, Zhiwei Wang, Lai Wang, Xi Yuan
Front Immunol. 2025.16:1449106 Electronic-eCollection
Source:PubMed
PMID: 39981246 doi:10.3389/fimmu.2025.1449106
Updated patent review for hematopoietic progenitor kinase (HPK1) inhibitors and degraders (2021-present).
Ying-Hui Yuan, Jia-Ying Mao, Ji-Fan Yue, Meng-Lan He, Zi Hui, Hang Yin, Jianshe Wang, Xiang-Yang Ye
Expert Opin Ther Pat. Feb 16, 2025.:1-22 Print-Electronic
Source:PubMed
PMID: 39950624 doi:10.1080/13543776.2025.2462834
Caspase-mediated cleavage and functional changes of hematopoietic progenitor kinase 1 (HPK1).
Y R Chen, C F Meyer, B Ahmed, Z Yao, T H Tan
Oncogene. Dec 02, 1999.18(51):7370-7 Print
Source:PubMed
PMID: 10602493 doi:10.1038/sj.onc.1203116
Functional interactions of HPK1 with adaptor proteins.
Jonathan S Boomer, Tse-Hua Tan
J Cell Biochem. May 01, 2005.95(1):34-44 Print
Source:PubMed
PMID: 15770651 doi:10.1002/jcb.20401
Caspase-cleaved HPK1 induces CD95L-independent activation-induced cell death in T and B lymphocytes.
Dirk Brenner, Alexander Golks, Mareike Becker, Wolfgang Müller, Christian R Frey, Rostislav Novak, Doron Melamed, Friedemann Kiefer, Peter H Krammer, Rüdiger Arnold
Blood. Dec 01, 2007.110(12):3968-77 Print-Electronic
Source:PubMed
PMID: 17712048 doi:10.1182/blood-2007-01-071167
Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020).
Ian D Linney, Neelu Kaila
Expert Opin Ther Pat. Oct, 2021.31(10):893-910 Print-Electronic
Source:PubMed
PMID: 33956554 doi:10.1080/13543776.2021.1924671
Caspase-mediated cleavage of hematopoietic progenitor kinase 1 (HPK1) converts an activator of NFkappaB into an inhibitor of NFkappaB.
R Arnold, J Liou, H C Drexler, A Weiss, F Kiefer
J Biol Chem. May 04, 2001.276(18):14675-84 Print-Electronic
Source:PubMed
PMID: 11278403 doi:10.1074/jbc.M008343200
Highly potent, orally active novel small-molecule HPK1 inhibitor DS21150768 induces anti-tumor responses in multiple syngeneic tumor mouse models.
Genzui Setsu, Megumi Goto, Kentaro Ito, Tomoe Taira, Masaya Miyamoto, Tomohiro Watanabe, Toru Taniguchi, Yuma Umezaki, Yusuke Nakazawa, Shuhei Uesugi, Kazuki Mori, Takao Horiuchi, Wataru Obuchi, Masako Minami, Takashi Shimada, Chisa Wada, Takanori Yoshida, Saito Higuchi
Eur J Pharmacol. Dec 15, 2023.961:176184 Print-Electronic
Source:PubMed
PMID: 37944847 doi:10.1016/j.ejphar.2023.176184
Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress.
Hui Chen, Xiangna Guan, Chi He, Tingting Lu, Xingyu Lin, Xuebin Liao
Expert Opin Ther Targets. Apr, 2024.28(4):237-250 Print-Electronic
Source:PubMed
PMID: 38650383 doi:10.1080/14728222.2024.2344697
0